Sitryx Therapeutics has appointed Adam Mostafa as its new Chief Financial Officer, bringing over 25 years of biotech financial experience, including previous roles at X4 Pharmaceuticals and Abpro Holdings.

Abpro and Celltrion presented preclinical data for their HER2 x CD3 T-cell engager ABP-102/CT-P72 at the AACR 2025 conference, suggesting potential for superior tumor selectivity, potent efficacy, and improved safety profile compared to existing HER2-targeted therapies.

Abpro Holdings, Inc. announced the departure of its CEO Ian Chan. The company's Board Chairman and CEO Miles Suk stated that this leadership transition does not affect the company's stability or direction, and they remain committed to their joint development with Celltrion and other key initiatives.